ClinicalTrials.gg
RecruitingNCT05190718R:IphEstUpdated Mar 7, 2025

Register Study: Implementation of Pharyngeal Electrostimulation Therapy for the Treatment of Acute Neurogenic Dysphagia

An observational study in Neurogenic Dysphagia, Traumatic Brain Injury and Stroke, sponsored by Karl Landsteiner University of Health Sciences. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by Karl Landsteiner University of Health Sciences · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Brain Injuries, Traumatic with a site in Austria — 3 open to participants now, 3 under way, none of them phase 3. Brain Injuries, Traumatic · Austria.

Started
2021
with 1 other
Observational
9 of 12
2 open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Karl Landsteiner University of Health Sciences

Among the 12 studies in Brain Injuries, Traumatic with a site in Austria, this one is one of 2 that started in 2021, is one of 9 observational ones, and was the 12th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

3 of the 12 studies in Brain Injuries, Traumatic with a site in Austria are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Brain Injuries, Traumatic with a site in Austria, or all of them as a file.
02

Study summary

Neurogenic dysphagia occurs with disruption of neurological systems or processes involved in the execution of coordinated and safe swallowing. It is common in patients with neurological diseases, in particular in patients treated in Intensive Care Units (ICU) who are intubated (up to 62%) and / or tracheotomised (up to 83%). Dysphagia is one of the most common and most dangerous symptoms of many neurological diseases. In addition, neurogenic dysphagia can have a significant impact on quality of life, medication efficacy, and malnutrition.

Dysphagia is currently treated conservatively on evidence-based exercises, individually adapted to each patient. In the recent years pharyngeal electrostimulation has been established and shown a positive impact on outcome. In fact, this type of therapy has not only become an addition to the existing therapy, but an important alternative for patients difficult to treat by other means.

The Phagenyx® is a medical device, which has lately been used more frequently in multiple hospitals for treatment of neurogenic dysphagia. For nearly two decades pharyngeal electrostimulation has been further developed and optimised. This therapy initiates changes in the swallowing motor cortex through neuroplasticity as well as local changes in peripheral sensory architecture associated with swallowing. Bath and colleagues (2020) recently reported the efficacy of pharyngeal electrostimulation (Phagenyx®) in various neurological conditions.

As a result, of current published studies, the use of pharyngeal electrostimulation probe, in selected patients, with neurological diseases with moderate to severe neurogenic dysphagia will be evaluated.

This trial will initially start as quality assurance project with the aim to extent it into a monocentric based register study.

The Investigators aim to validate the effectiveness of pharyngeal electrostimulation for the treatment of moderate to severe neurogenic dysphagia by systematically recording specific dysphagia-relevant parameters. At present, it is still uncertain to what extent patients with neurogenic dysphagia in the context of a non-acute neurological disease could benefit from this method.

The research questions:

Does the use of the pharyngeal electrostimulation probe have an influence on the outcome of dysphagia in patients with moderate to severe neurogenic dysphagia? How long after therapy, can the use of the pharyngeal electrostimulation probe lead to oral food intake and/or removal of a tracheal cannula?

Read the detailed description

Neurogenic dysphagia occurs with disruption of neurological systems or processes involved in the execution of coordinated and safe swallowing. It is common in patients with neurological diseases, in particular in patients treated in Intensive Care Units (ICU) who are intubated (up to 62%) and / or tracheotomised (up to 83%). Dysphagia is one of the most common and most dangerous symptoms of many neurological diseases. For example, dysphagia is found in 50% - 60% of all patients suffering a stroke or a traumatic brain injury. These patients are 4-times more likely to develop aspiration pneumonia and have a higher mortality rate. In patients with Parkinson's disease, pneumonia due to dysphagia is the most common cause of death. In addition, neurogenic dysphagia can have a significant impact on quality of life, medication efficacy, and malnutrition. Patients with neurogenic dysphagia, undergo standardized screening and, if indicated, a complementary dysphagia assessment as soon as possible to ensure the best possible care.

Dysphagia used to be treated conservatively with programmes of evidence-based exercises, individually adapted to each patient. In the recent years pharyngeal electrostimulation has been established and shown a positive impact on outcome. In fact, this type of therapy has not only become an addition to the existing therapy, but an important alternative for patients difficult to treat by other means.

The Phagenyx® is a medical device, which has lately been used more frequently in multiple hospitals for treatment of neurogenic dysphagia. For nearly two decades pharyngeal electrostimulation has been further developed and optimised. This therapy initiates changes in the swallowing motor cortex through neuroplasticity as well as local changes in peripheral sensory architecture associated with swallowing. Bath and colleagues recently reported the efficacy of pharyngeal electrostimulation (Phagenyx®) in various neurological conditions.

As a result of current published studies, the use of pharyngeal electrostimulation probe in selected patients with neurological diseases with moderate to severe neurogenic dysphagia will be evaluated.

This trial will initially start as quality assurance project with the aim to extent it into a multicentre based register study.

Objective:

The investigators aim to demonstrate the effectiveness of pharyngeal electrostimulation for the treatment of moderate to severe neurogenic dysphagia by systematically recording specific dysphagia-relevant parameters. At present, it is still uncertain to what extent patients with neurogenic dysphagia in the context of a non-acute neurological disease could benefit from this method.

The research questions can be formulated as follows:

Does the use of the pharyngeal electrostimulation probe have an influence on the outcome of dysphagia in patients with moderate to severe neurogenic dysphagia? In what period of time after therapy can the use of the pharyngeal electrostimulation probe lead to oral food intake and/or removal of a tracheal cannula?

Study Design / Methodology:

The project will be carried out as a register study as part of a quality assurance project. All patients with moderate to severe neurogenic dysphagia, who show a potential for rehabilitation, will be included. The severity of dysphagia will first be classified with clinically validated screenings and scores. These tests include the Gugging Swallowing Screen (GUSS), the Dysphagia Severity Rating Scale (DSRS) and the Bogenhausen Dysphagia Score (BODS 1+2). The Fibreoptic Endoscopic Evaluation of Swallowing (FEES), the golden standard for dysphagia classification, is used as instrumental assessment. In the setting of these standardized tests, the investigators will perform the validated Penetration Aspiration Scale (PAS) and Secretion Severity Scale (SSS) to evaluate dysphagia severity. These data will be collected prior to stimulation therapy.

Pharyngeal stimulation therapy follows a standardised protocol. A special feeding tube (Phagenyx®) equipped with stimulation electrodes is placed in the stomach via the nasopharynx. It can be used for both therapy and nutrition and remains in the patient like a conventional feeding tube. The therapy is performed with a stimulation device connected to the nasogastric catheter. For cooperative patients an individual stimulation threshold (value in milliampere (mA)); stimulation threshold / tolerance limit) is determined. Based on 3 values for lower threshold and 3 values for upper threshold level the optimal stimulation value is calculated. The electrostimulation therapy takes place for a duration of 10 minutes at this value. In non-cooperative patients, a standardised 12 milliampere (mA) value is administered. A maximum of 6 treatments in total can be delivered to the patient after which point the catheter will be electronically locked to prevent further treatments from being delivered to the patient.

Treatment Regime and Rules:

The first treatment may take place from 2 hours post catheter insertion. The sessions should ideally take place on consecutive days but the interval must be no longer than 48 hours between completed sessions and no shorter than 14 hours. This is monitored and controlled by the Base Station software. There is no upper limit on the interval between the 3rd and 4th treatments to provide an opportunity for patient assessment. The software is designed to deliver electrical stimulus for 10 minutes in each session. The session may be manually paused by the operator if required or automatically by the Base Station if it detects an electrode contact problem. In either case, the treatment must be continued within 4 minutes of the pause initiation or else the session is classified as incomplete and must be repeated. In the event of an incomplete session, and if the patient agrees to continue with treatment, it is possible to attempt to retry a session up to 2 more times within that 14-hour period. The Base Station is designed to check the quality of contact for each pulse of stimulus delivered (5 pulses per second). In the event that contact quality falls below the acceptable level for a continuous period of 10 seconds then the software will alert the operator and automatically pause the session. This then provides an opportunity for the operator to adjust the position of the catheter or patient in order to restore contact. If the 48 hour interval between the treatments is unavoidably exceeded, then the treatment counter in the software is re-set and some treatments must be repeated. The counter is re-set to zero if the 48 hour interval is exceeded in between any of the first three treatments. The counter is re-set to 3 if the interval is exceeded after 3 treatments have already been delivered. Note: The 48 hour maximum interval does not apply between treatment 3 and 4 in order to allow the user to assess patient response to the standard three treatment sessions. In the event the 48 hour limit is unavoidably exceeded on multiple occasions due to problems (and the treatment counter re-set to zero more than once) as many as 9 complete treatments may theoretically be delivered. No more than 15 treatment sessions (made up of both complete and incomplete treatments) are allowed for a single patient.

Methodology:

This study is conducted in 3 phases. Phase 1: Neurological and dysphagic parameters are systematically assessed with the following routine examinations. The modified Ranking Scale (mRS), the NIHSS, as well as a Bedside swallowing screening procedure (GUSS) and scales and scores for food intake (DSRS, BODS 1+2) are collected.

Furthermore, the Golden Standard for swallowing diagnostics, the Fibreoptic Endoscopic Evaluation of Swallowing (FEES), is carried out to evaluate the swallowing pathology and classify its severity.

Phase 2: pharyngeal stimulation is performed via a nasogastric probe (Phagenyx) for a duration of 10 minutes daily and for at least 3 consecutive days. The number of stimulation repeats depends on therapy progress (max 6 stimulations) and an interdisciplinary re-evaluation of the patient's rehabilitation potential. This allows for decision making regarding further rehabilitation steps. At the end of stimulation, the same parameters as before are measured.

Phase 3: takes place before the patient's discharge from hospital and includes a final re-examination using the same dysphagia and neurological parameters to document long-term effects.

03

Conditions studied

  • Neurogenic Dysphagia
  • Traumatic Brain Injury
  • Stroke
  • Dysphagia
  • Long Covid-19
  • Intubation Complication
  • Polyradiculitis

Keywords

  • Neurogenic Dysphagia
  • Dysphagia
  • Traumatic Brain Injury
  • Phagenyx
  • Stroke
  • Pharyngeal electrical stimulation
  • Long Covid-19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with neurogenic dysphagia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neurogenic dysphagia

    • Ischaemic and haemorrhagic strokes
    • Infra- as well as supra-tentorial
    • Polyradiculitis
    • Parkinson's disease
    • Multiple sclerosis
    • Dementia
    • Traumatic brain injury
    • Post Covid-19 pat.
  • patients over the age of 18.

Exclusion criteria

Exclusion Criteria:

  • to nasogastric tube,
  • Unstable cardiac or respiratory condition that does not allow the insertion of the Nasogastric tube
  • Pacemakers
  • Implanted defibrillators (ICD)
  • Pregnant
  • Breastfeeding women

(Caution: interfering signals may be visible in ECGs, \& EEGs with continuous recording).

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
90 Days
Patient registry
Yes

Groups and cohorts

  • Dysphagia rehabilitation

    All interventions are part of routine treatment of dysphagia.

    Device: Pharyngeal electrostimulation

Interventions

  • DevicePharyngeal electrostimulation

    Routine treatment: Pharyngeal stimulation is performed via a nasogastric probe (Phagenyx) for a duration of 10 minutes daily and for at least 3 consecutive days. The number of stimulation repeats until max 2x3 repeats, depends on therapy progress and an interdisciplinary re-evaluation of the patient's rehabilitation potential.

    Also known as: Phagenyx

06

What researchers measure

Primary outcomes

  1. Dysphagia Severity Rating Scale (DSRS)

    The Dysphagia Severity Rating Scale (DSRS) describe the capacity of the patient to swallow food and fluids and if the patient needs help. The scale range from 0-12. 0= no dysphagia 12= severe dysphagia

    Time frame: through study completion, an average of 1 year

  2. Penetration Aspiration Scale (PAS)

    Penetration Aspiration Scale (PAS) is measured during the Swallow endoscopy (FEES). The PAS is a measure of the penetration and aspiration of a bolus. In this study the investigators evaluate two semisolid and three liquid boluses. Scala ranges from 1-8. 1. Material does not enter the airway 2. Material enters the airway, remains above the vocal folds, and is ejected from the airway 3. Material enters the airway, remains above the vocal folds, and is not ejected from the airway 4. Material enters the airway, contacts the vocal folds, and is ejected from the airway 5. Material enters the airway, contacts the vocal folds, and is not ejected from the airway 6. Material enters the airway, passes below the vocal folds and is ejected into the larynx or out of the airway 7. Material enters the airway, passes below the vocal folds, and is not ejected from the trachea despite effort 8. Material enters the airway, passes below the vocal folds, and no effort is made to eject

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • University Clinic Tulln
    Tulln, Low Austria 3430, Austria
    Recruiting
08

References and documents

Publications

  • Bath PM, Scutt P, Love J, Clave P, Cohen D, Dziewas R, Iversen HK, Ledl C, Ragab S, Soda H, Warusevitane A, Woisard V, Hamdy S; Swallowing Treatment Using Pharyngeal Electrical Stimulation (STEPS) Trial Investigators. Pharyngeal Electrical Stimulation for Treatment of Dysphagia in Subacute Stroke: A Randomized Controlled Trial. Stroke. 2016 Jun;47(6):1562-70. doi: 10.1161/STROKEAHA.115.012455. Epub 2016 May 10. PubMed 27165955 ↗
  • Bath PM, Woodhouse LJ, Suntrup-Krueger S, Likar R, Koestenberger M, Warusevitane A, Herzog J, Schuttler M, Ragab S, Everton L, Ledl C, Walther E, Saltuari L, Pucks-Faes E, Bocksrucker C, Vosko M, de Broux J, Haase CG, Raginis-Zborowska A, Mistry S, Hamdy S, Dziewas R; for PHADER Investigators. Pharyngeal electrical stimulation for neurogenic dysphagia following stroke, traumatic brain injury or other causes: Main results from the PHADER cohort study. EClinicalMedicine. 2020 Nov 10;28:100608. doi: 10.1016/j.eclinm.2020.100608. eCollection 2020 Nov. PubMed 33294818 ↗
  • Brodsky MB, Levy MJ, Jedlanek E, Pandian V, Blackford B, Price C, Cole G, Hillel AT, Best SR, Akst LM. Laryngeal Injury and Upper Airway Symptoms After Oral Endotracheal Intubation With Mechanical Ventilation During Critical Care: A Systematic Review. Crit Care Med. 2018 Dec;46(12):2010-2017. doi: 10.1097/CCM.0000000000003368. PubMed 30096101 ↗
  • Brodsky MB, Nollet JL, Spronk PE, Gonzalez-Fernandez M. Prevalence, Pathophysiology, Diagnostic Modalities, and Treatment Options for Dysphagia in Critically Ill Patients. Am J Phys Med Rehabil. 2020 Dec;99(12):1164-1170. doi: 10.1097/PHM.0000000000001440. PubMed 32304381 ↗
  • Dziewas R, Auf dem Brinke M, Birkmann U, Brauer G, Busch K, Cerra F, Damm-Lunau R, Dunkel J, Fellgiebel A, Garms E, Glahn J, Hagen S, Held S, Helfer C, Hiller M, Horn-Schenk C, Kley C, Lange N, Lapa S, Ledl C, Lindner-Pfleghar B, Mertl-Rotzer M, Muller M, Neugebauer H, Ozsucu D, Ohms M, Perniss M, Pfeilschifter W, Plass T, Roth C, Roukens R, Schmidt-Wilcke T, Schumann B, Schwarze J, Schweikert K, Stege H, Theuerkauf D, Thomas RS, Vahle U, Voigt N, Weber H, Werner CJ, Wirth R, Wittich I, Woldag H, Warnecke T. Safety and clinical impact of FEES - results of the FEES-registry. Neurol Res Pract. 2019 Apr 26;1:16. doi: 10.1186/s42466-019-0021-5. eCollection 2019. PubMed 33324882 ↗
  • BARTOLOME, G.,& SCHRÖTER-MORASCH, H. H. 2006. Der Bogenhausener Dysphagiescore - BODS In: Schluckstörungen, München. Jena, Urban & Fischer Verlag.
  • Dziewas R, Glahn J, Helfer C, Ickenstein G, Keller J, Lapa S, Ledl C, Lindner-Pfleghar B, Nabavi D, Prosiegel M, Riecker A, Stanschus S, Warnecke T, Busse O. [FEES for neurogenic dysphagia: training curriculum of the German Society of Neurology and the German Stroke Society]. Nervenarzt. 2014 Aug;85(8):1006-15. doi: 10.1007/s00115-014-4114-7. German. PubMed 25060752 ↗
  • Dziewas R, Mistry S, Hamdy S, Minnerup J, Van Der Tweel I, Schabitz W, Bath PM; PHAST-TRAC Investigators. Design and implementation of Pharyngeal electrical Stimulation for early de-cannulation in TRACheotomized (PHAST-TRAC) stroke patients with neurogenic dysphagia: a prospective randomized single-blinded interventional study. Int J Stroke. 2017 Jun;12(4):430-437. doi: 10.1177/1747493016676618. Epub 2016 Nov 2. PubMed 27807279 ↗
  • Dziewas R., Pflug C. et al., Neurogene Dysphagie, S1-Leitlinie, 2020, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien (abgerufen am 02.07.2021)
  • Dziewas R, Stellato R, van der Tweel I, Walther E, Werner CJ, Braun T, Citerio G, Jandl M, Friedrichs M, Notzel K, Vosko MR, Mistry S, Hamdy S, McGowan S, Warnecke T, Zwittag P, Bath PM; PHAST-TRAC investigators. Pharyngeal electrical stimulation for early decannulation in tracheotomised patients with neurogenic dysphagia after stroke (PHAST-TRAC): a prospective, single-blinded, randomised trial. Lancet Neurol. 2018 Oct;17(10):849-859. doi: 10.1016/S1474-4422(18)30255-2. Epub 2018 Aug 28. PubMed 30170898 ↗
  • Everton LF, Benfield JK, Hedstrom A, Wilkinson G, Michou E, England TJ, Dziewas R, Bath PM, Hamdy S. Psychometric assessment and validation of the dysphagia severity rating scale in stroke patients. Sci Rep. 2020 Apr 29;10(1):7268. doi: 10.1038/s41598-020-64208-9. PubMed 32350338 ↗
  • Florea C, Braumann C, Mussger C, Leis S, Hauer L, Sellner J, Golaszewski SM. Therapy of Dysphagia by Prolonged Pharyngeal Electrical Stimulation (Phagenyx) in a Patient with Brainstem Infarction. Brain Sci. 2020 Apr 28;10(5):256. doi: 10.3390/brainsci10050256. PubMed 32353976 ↗
  • Koestenberger M, Neuwersch S, Hoefner E, Breschan C, Weissmann H, Stettner H, Likar R. A Pilot Study of Pharyngeal Electrical Stimulation for Orally Intubated ICU Patients with Dysphagia. Neurocrit Care. 2020 Apr;32(2):532-538. doi: 10.1007/s12028-019-00780-x. PubMed 31313142 ↗
  • Martino R, Foley N, Bhogal S, Diamant N, Speechley M, Teasell R. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. Stroke. 2005 Dec;36(12):2756-63. doi: 10.1161/01.STR.0000190056.76543.eb. Epub 2005 Nov 3. PubMed 16269630 ↗
  • Trapl M, Enderle P, Nowotny M, Teuschl Y, Matz K, Dachenhausen A, Brainin M. Dysphagia bedside screening for acute-stroke patients: the Gugging Swallowing Screen. Stroke. 2007 Nov;38(11):2948-52. doi: 10.1161/STROKEAHA.107.483933. Epub 2007 Sep 20. PubMed 17885261 ↗
  • Warnecke T, Im S, Kaiser C, Hamacher C, Oelenberg S, Dziewas R. Aspiration and dysphagia screening in acute stroke - the Gugging Swallowing Screen revisited. Eur J Neurol. 2017 Apr;24(4):594-601. doi: 10.1111/ene.13251. Epub 2017 Feb 3. PubMed 28322006 ↗

Individual participant data

Plan to share: Undecided — It is not yet clear, if the data will be shared or not.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2025, 47 months after the start.

Of 231 non-industry observational studies under Brain Injuries, Traumatic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 95. This study's planned 47 months is close to that.

Counting every sponsor, half of 253 studies reached it within 49 months; a quarter within 23 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2021
First posted
Jan 13, 2022
StartActual
Dec 15, 2021
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 30, 2026
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05190718
Lead sponsor
Karl Landsteiner University of Health Sciences
Collaborators
Universitätsklinikum Tulln
Responsible party
Michaela Trapl-Grundschober (PhDr. Michaela Trapl-Grundschober, MSc, Departement of Clinical Neurology, Speech Therapist, Karl Landsteiner University of Health Sciences) — Principal investigator
First posted
Jan 13, 2022
Start date
Dec 15, 2021
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Mar 7, 2025

Study contacts

Michaela Trapl-Grundschober, MAS, MSc
Contact
michaela.trapl@tulln.lknoe.at
+43 2272900422393
Walter Struhal, Prof. Dr.
study chair · University Clinic Tulln

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion